Metabolism and atherogenic disease association of lysophosphatidylcholine

Atherosclerosis

Volumn 208, Issue 1, 2010, Pages 10-18

  Schmitz, Gerd ^a   Ruebsaamen, Katharina ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

G protein coupled receptor; Lipid species; Lipidomics; Lysophospholipids; Phospholipase; Signalling

Indexed keywords

ALKALOID; BIOLOGICAL MARKER; CHOLINE; FATTY ACID; FLAVONOID; G PROTEIN COUPLED RECEPTOR; GLYCEROPHOSPHOLIPID; LYSOPHOSPHATIDYLCHOLINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLGLYCEROL; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PRAVASTATIN; TERPENE; VARESPLADIB;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG DESIGN; HUMAN; INFLAMMATION; LIPID ANALYSIS; MASS SPECTROMETRY; METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ATHEROSCLEROSIS; HUMANS; LYSOPHOSPHATIDYLCHOLINES;

EID: 73449097463     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.05.029     Document Type: Review

References (144)

1. Hla T., Lee M.J., Ancellin N., Paik J.H., and Kluk M.J. Lysophospholipids-receptor revelations. Science 294 (2001) 1875-1878
2. Birgbauer E., and Chun J. New developments in the biological functions of lysophospholipids. Cell Mol Life Sci 63 (2006) 2695-2701
3. Fukushima N., Ishii I., Contos J.J., Weiner J.A., and Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol 41 (2001) 507-534
4. Gardell S.E., Dubin A.E., and Chun J. Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 12 (2006) 65-75
5. Meyer zu H.D., and Jakobs K.H. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta 1768 (2007) 923-940
6. Torkhovskaya T.I., Ipatova O.M., Zakharova T.S., Kochetova M.M., and Khalilov E.M. Lysophospholipid receptors in cell signaling. Biochemistry (Mosc.) 72 (2007) 125-131
7. Xu Y., Xiao Y.J., Zhu K., et al. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 3 (2003) 23-32
8. Boggs K.P., Rock C.O., and Jackowski S. Lysophosphatidylcholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine inhibit the CDP-choline pathway of phosphatidylcholine synthesis at the CTP: phosphocholine cytidylyltransferase step. J Biol Chem 270 (1995) 7757-7764
9. Vance D., and Vance J. Phospholipid biosynthesis in eukaryotes. In: Vance D., and Vance J. (Eds). Biochemistry of lipids, lipoproteins, and membranes (2008), Elsevier, Amsterdam 213-245
10. Gauster M., Rechberger G., Sovic A., et al. Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine. J Lipid Res 46 (2005) 1517-1525
11. Lima V.L.M., Coehlo L.C.B.B., Kennedy J.F., and Dolphin P.J. Lecithin-cholesterol acyltransferase (LCAT) as a plasma glycoprotein: an overview. Carbohyd Polym 55 (2004) 179-191
12. Sekas G., Patton G.M., Lincoln E.C., and Robins S.J. Origin of plasma lysophosphatidylcholine: evidence for direct hepatic secretion in the rat. J Lab Clin Med 105 (1985) 190-194
13. Hessler J.R., Morel D.W., Lewis L.J., and Chisolm G.M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3 (1983) 215-222
14. Steinbrecher U.P., Parthasarathy S., Leake D.S., Witztum J.L., and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 81 (1984) 3883-3887
15. Ali S., Davis M.G., Becker M.W., and Dorn G.W. Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem 268 (1993) 17397-17403
16. Negre-Salvayre A., Lopez M., Levade T., et al. Ultraviolet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. II. Uptake and cytotoxicity of ultraviolet-treated LDL on lymphoid cell lines. Biochim Biophys Acta 1045 (1990) 224-232
17. Ehrenwald E., Chisolm G.M., and Fox P.L. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest 93 (1994) 1493-1501
18. Cathcart M.K., McNally A.K., and Chisolm G.M. Lipoxygenase-mediated transformation of human low density lipoprotein to an oxidized and cytotoxic complex. J Lipid Res 32 (1991) 63-70
19. Savenkova M.L., Mueller D.M., and Heinecke J.W. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 269 (1994) 20394-20400
20. Berliner J.A., Territo M.C., Sevanian A., et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85 (1990) 1260-1266
21. Heinecke J.W., Rosen H., and Chait A. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 74 (1984) 1890-1894
22. Morel D.W., DiCorleto P.E., and Chisolm G.M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 4 (1984) 357-364
23. Umezu-Goto M., Kishi Y., Taira A., et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158 (2002) 227-233
24. Matsumoto T., Kobayashi T., and Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 14 (2007) 3209-3220
25. Liu E., Goldhaber J.I., and Weiss J.N. Effects of lysophosphatidylcholine on electrophysiological properties and excitation-contraction coupling in isolated guinea pig ventricular myocytes. J Clin Invest 88 (1991) 1819-1832
26. Croset M., Brossard N., Polette A., and Lagarde M. Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 345 Pt 1 (2000) 61-67
27. 2+ system in HL-60 leukaemia cells. Biochem J 336 Pt 2 (1998) 491-500
28. Okita M., Gaudette D.C., Mills G.B., and Holub B.J. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine (lysoPC) in ovarian cancer patients. Int J Cancer 71 (1997) 31-34
29. Sasagawa T., Suzuki K., Shiota T., Kondo T., and Okita M. The significance of plasma lysophospholipids in patients with renal failure on hemodialysis. J Nutr Sci Vitaminol (Tokyo) 44 (1998) 809-818
30. Rabini R.A., Galassi R., Fumelli P., et al. Reduced Na(+)-K(+)-ATPase activity and plasma lysophosphatidylcholine concentrations in diabetic patients. Diabetes 43 (1994) 915-919
31. Subbaiah P.V., Chen C.H., Bagdade J.D., and Albers J.J. Substrate specificity of plasma lysolecithin acyltransferase and the molecular species of lecithin formed by the reaction. J Biol Chem 260 (1985) 5308-5314
32. Chen L., Liang B., Froese D.E., et al. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of lysophosphatidylcholine composition on vascular relaxation. J Lipid Res 38 (1997) 546-553
33. Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal transduction. Biochim Biophys Acta 1582 (2002) 81-88
34. Marathe G.K., Silva A.R., de Castro Faria Neto H.C., et al. Lysophosphatidylcholine and lyso-PAF display PAF-like activity derived from contaminating phospholipids. J Lipid Res 42 (2001) 1430-1437
35. Subra C., Laulagnier K., Perret B., and Record M. Exosome lipidomics unravels lipid sorting at the level of multivesicular bodies. Biochimie 89 (2007) 205-212
36. Martin-Valmaseda E.M., Sanchez-Yague J., Hernandez-Hernandez A., and Llanillo M. Vesiculation and changes in fluidity and lipid composition of platelet membranes after storage of sheep platelets in plasma or Seto solution. Thromb Haemost 80 (1998) 668-676
37. Weerheim A.M., Kolb A.M., Sturk A., and Nieuwland R. Phospholipid composition of cell-derived microparticles determined by one-dimensional high-performance thin-layer chromatography. Anal Biochem 302 (2002) 191-198
38. Stremler K.E., Stafforini D.M., Prescott S.M., and McIntyre T.M. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem 266 (1991) 11095-11103
39. Chisolm III G.M., and Chai Y. Regulation of cell growth by oxidized LDL. Free Radic Biol Med 28 (2000) 1697-1707
40. Soga T., Ohishi T., Matsui T., et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 326 (2005) 744-751
41. Radu C.G., Yang L.V., Riedinger M., Au M., and Witte O.N. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc Natl Acad Sci USA 101 (2004) 245-250
42. Yang L.V., Radu C.G., Wang L., Riedinger M., and Witte O.N. Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood 105 (2005) 1127-1134
43. Le L.Q., Kabarowski J.H., Weng Z., et al. Mice lacking the orphan G protein-coupled receptor G2A develop a late-onset autoimmune syndrome. Immunity 14 (2001) 561-571
44. Qiao J., Huang F., Naikawadi R.P., Kim K.S., Said T., and Lum H. Lysophosphatidylcholine impairs endothelial barrier function through the G protein-coupled receptor GPR4. Am J Physiol Lung Cell Mol Physiol 291 (2006) L91-101
45. Sin W.C., Zhang Y., Zhong W., et al. G protein-coupled receptors GPR4 and TDAG8 are oncogenic and overexpressed in human cancers. Oncogene 23 (2004) 6299-6303
46. Aoki Y., Nakamura M., Kodama H., Matsumoto T., Shimizu T., and Noma M. A radioreceptor binding assay for platelet-activating factor (PAF) using membranes from CHO cells expressing human PAF receptor. J Immunol Methods 186 (1995) 225-231
47. Huang Y.H., Schafer-Elinder L., Wu R., Claesson H.E., and Frostegard J. Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol 116 (1999) 326-331
48. Ishii S., and Shimizu T. Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice. Prog Lipid Res 39 (2000) 41-82
49. 2+ signaling via the platelet-activating factor receptor in macrophages. Am J Physiol 272 (1997) H17-H24
50. Hara S., Shike T., Takasu N., and Mizui T. Lysophosphatidylcholine promotes cholesterol efflux from mouse macrophage foam cells. Arterioscler Thromb Vasc Biol 17 (1997) 1258-1266
51. Prokazova N.V., Zvezdina N.D., and Korotaeva A.A. Effect of lysophosphatidylcholine on transmembrane signal transduction. Biochemistry (Mosc.) 63 (1998) 31-37
52. Bassa B.V., Roh D.D., Vaziri N.D., Kirschenbaum M.A., and Kamanna V.S. Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways. Am J Physiol 277 (1999) F328-F337
53. Jing Q., Xin S.M., Zhang W.B., Wang P., Qin Y.W., and Pei G. Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis. Circ Res 87 (2000) 52-59
54. Yuan Y., Schoenwaelder S.M., Salem H.H., and Jackson S.P. The bioactive phospholipid, lysophosphatidylcholine, induces cellular effects via G-protein-dependent activation of adenyl cyclase. J Biol Chem 271 (1996) 27090-27098
55. Aiyar N., Disa J., Ao Z., et al. Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells. Mol Cell Biochem 295 (2007) 113-120
56. Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., and Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 12 (2006) RA5-16
57. Heermeier K., Schneider R., Heinloth A., Wanner C., Dimmeler S., and Galle J. Oxidative stress mediates apoptosis induced by oxidized low-density lipoprotein and oxidized lipoprotein(a). Kidney Int 56 (1999) 1310-1312
58. Portman O.W., and Alexander M. Lysophosphatidylcholine concentrations and metabolism in aortic intima plus inner media: effect of nutritionally induced atherosclerosis. J Lipid Res 10 (1969) 158-165
59. Thukkani A.K., McHowat J., Hsu F.F., Brennan M.L., Hazen S.L., and Ford D.A. Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation 108 (2003) 3128-3133
60. Burke J.E., and Dennis E.A. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 23 (2009) 49-59
61. Rosenson R.S. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 23 (2009) 93-101
62. Jonsson-Rylander A.C., Lundin S., Rosengren B., Pettersson C., and Hurt-Camejo E. Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 10 (2008) 252-259
63. Rosengren B., Jonsson-Rylander A.C., Peilot H., Camejo G., and Hurt-Camejo E. Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochim Biophys Acta 1761 (2006) 1301-1308
64. Koenig W., and Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 23 (2009) 85-92
65. Hartford M., Wiklund O., Mattsson H.L., et al. CRP, interleukin-6, secretory phospholipase A2 group IIA, and intercellular adhesion molecule-1 during the early phase of acute coronary syndromes and long-term follow-up. Int J Cardiol 108 (2006) 55-62
66. Pruzanski W., Lambeau G., Lazdunski M., Cho W., Kopilov J., and Kuksis A. Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2. Biochim Biophys Acta 1771 (2007) 5-19
67. Camejo G., Hurt-Camejo E., Wiklund O., and Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 139 (1998) 205-222
68. Boyanovsky B.B., and Webb N.R. Biology of secretory phospholipase A2. Cardiovasc Drugs Ther 23 (2009) 61-72
69. Hakala J.K., Oorni K., Pentikainen M.O., Hurt-Camejo E., and Kovanen P.T. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 21 (2001) 1053-1058
70. Stafforini D.M. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 23 (2009) 73-83
71. Zalewski A., and Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25 (2005) 923-931
72. Marathe G.K., Harrison K.A., Murphy R.C., Prescott S.M., Zimmerman G.A., and McIntyre T.M. Bioactive phospholipid oxidation products. Free Radic Biol Med 28 (2000) 1762-1770
73. Anderson J.L. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 101 (2008) 23F-33F
74. Corson M.A., Jones P.H., and Davidson M.H. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 101 (2008) 41F-50F
75. Nanda B.L., Nataraju A., Rajesh R., Rangappa K.S., Shekar M.A., and Vishwanath B.S. PLA2 mediated arachidonate free radicals: PLA2 inhibition and neutralization of free radicals by anti-oxidants-a new role as anti-inflammatory molecule. Curr Top Med Chem 7 (2007) 765-777
76. Shaposhnik Z., Wang X., Trias J., Fraser H., and Lusis A.J. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002). J Lipid Res 50 (2009) 623-629
77. van den B.H., and Aarsman A.J. A review on methods of phospholipase A determination. Agents Actions 9 (1979) 382-389
78. Choi S., Lee Y.S., Na D.S., and Yoo Y.S. Determination of enzymatic activity and properties of secretory phospholipase A2 by capillary electrophoresis. J Chromatogr A 853 (1999) 285-293
79. Lai C.S., Zhang J.Z., and Joseph J. Spin-label assay for phospholipase A2. Anal Biochem 172 (1988) 397-402
80. Rawyler A., and Siegenthaler P.A. A single and continuous spectrophotometric assay for various lipolytic enzymes, using natural, non-labelled lipid substrates. Biochim Biophys Acta 1004 (1989) 337-344
81. Fuchs B., Schiller J., Wagner U., Hantzschel H., and Arnold K. The phosphatidylcholine/lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem 38 (2005) 925-933
82. Catz S.D., and Sterin-Speziale N.B. Bradykinin stimulates phosphoinositide turnover and phospholipase C but not phospholipase D and NADPH oxidase in human neutrophils. J Leukoc Biol 59 (1996) 591-597
83. Wang W.Q., and Gustafson A. One-dimensional thin-layer chromatographic separation of phospholipids and lysophospholipids from tissue lipid extracts. J Chromatogr 581 (1992) 139-142
84. Yokoyama K., Shimizu F., and Setaka M. Simultaneous separation of lysophospholipids from the total lipid fraction of crude biological samples using two-dimensional thin-layer chromatography. J Lipid Res 41 (2000) 142-147
85. Guan Z., Grunler J., Piao S., and Sindelar P.J. Separation and quantitation of phospholipids and their ether analogues by high-performance liquid chromatography. Anal Biochem 297 (2001) 137-143
86. Suchocka Z., Gronostajska D., Suchocki P., and Pachecka J. New HPLC method for separation of blood plasma phospholipids. J Pharm Biomed Anal 32 (2003) 859-865
87. Pruzanski W., Stefanski E., de Beer F.C., de Beer M.C., Ravandi A., and Kuksis A. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 41 (2000) 1035-1047
88. Xiao Y., Chen Y., Kennedy A.W., Belinson J., and Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 905 (2000) 242-259
89. Murph M., Tanaka T., Pang J., et al. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433 (2007) 1-25
90. Petkovic M., Muller J., Muller M., Schiller J., Arnold K., and Arnhold J. Application of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring the digestion of phosphatidylcholine by pancreatic phospholipase A(2). Anal Biochem 308 (2002) 61-70
91. Cai S., Huo T., Li N., Xiong Z., and Li F. Lysophosphatidylcholine-biomarker of Metformin action: studied using UPLC/MS/MS. Biomed Chromatogr (2009)
92. Pang L.Q., Liang Q.L., Wang Y.M., Ping L., and Luo G.A. Simultaneous determination and quantification of seven major phospholipid classes in human blood using normal-phase liquid chromatography coupled with electrospray mass spectrometry and the application in diabetes nephropathy. J Chromatogr B Analyt Technol Biomed Life Sci 869 (2008) 118-125
93. Smith J.C., Hou W., Whitehead S.N., Ethier M., Bennett S.A., and Figeys D. Identification of lysophosphatidylcholine (LPC) and platelet activating factor (PAF) from PC12 cells and mouse cortex using liquid chromatography/multi-stage mass spectrometry (LC/MS3). Rapid Commun Mass Spectrom 22 (2008) 3579-3587
94. Takatera A., Takeuchi A., Saiki K., Morisawa T., Yokoyama N., and Matsuo M. Quantification of lysophosphatidylcholines and phosphatidylcholines using liquid chromatography-tandem mass spectrometry in neonatal serum. J Chromatogr B Analyt Technol Biomed Life Sci 838 (2006) 31-36
95. Davis B., Koster G., Douet L.J., et al. Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein. J Biol Chem 283 (2008) 6428-6437
96. Hsu F.F., and Turk J. Electrospray ionization/tandem quadrupole mass spectrometric studies on phosphatidylcholines: the fragmentation processes. J Am Soc Mass Spectrom 14 (2003) 352-363
97. Liebisch G., Drobnik W., Lieser B., and Schmitz G. High-throughput quantification of lysophosphatidylcholine by electrospray ionization tandem mass spectrometry. Clin Chem 48 (2002) 2217-2224
98. Kabarowski J.H., Xu Y., and Witte O.N. Lysophosphatidylcholine as a ligand for immunoregulation. Biochem Pharmacol 64 (2002) 161-167
99. Leidl K., Liebisch G., Richter D., and Schmitz G. Mass spectrometric analysis of lipid species of human circulating blood cells. Biochim Biophys Acta 1781 (2008) 655-664
100. Yan J.J., Jung J.S., Lee J.E., et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 10 (2004) 161-167
101. Drobnik W., Liebisch G., Audebert F.X., et al. Plasma ceramide and lysophosphatidylcholine inversely correlate with mortality in sepsis patients. J Lipid Res 44 (2003) 754-761
102. Hirano K., Ito T., Morihara H., Tanaka T., and Satouchi K. Cytosolic lysophosphatidylcholine/transacylase in the production of dipolyunsaturated phosphatidylcholine in bonito muscle. FEBS Lett 437 (1998) 193-196
103. Dawson R.M., Irvine R.F., Hemington N.L., and Hirasawa K. The alkaline phospholipase A1 of rat liver cytosol. Biochem J 209 (1983) 865-872
104. Granata F., Balestrieri B., Petraroli A., Giannattasio G., Marone G., and Triggiani M. Secretory phospholipases A2 as multivalent mediators of inflammatory and allergic disorders. Int Arch Allergy Immunol 131 (2003) 153-163
105. Jenkins G.M., and Frohman M.A. Phospholipase D: a lipid centric review. Cell Mol Life Sci 62 (2005) 2305-2316
106. Chen S., and Subbaiah P.V. Phospholipid and fatty acid specificity of endothelial lipase: potential role of the enzyme in the delivery of docosahexaenoic acid (DHA) to tissues. Biochim Biophys Acta 1771 (2007) 1319-1328
107. Shamburek R.D., Zech L.A., Cooper P.S., Vandenbroek J.M., and Schwartz C.C. Disappearance of two major phosphatidylcholines from plasma is predominantly via LCAT and hepatic lipase. Am J Physiol 271 (1996) E1073-E1082
108. Perret B., Mabile L., Martinez L., Terce F., Barbaras R., and Collet X. Hepatic lipase: structure/function relationship, synthesis, and regulation. J Lipid Res 43 (2002) 1163-1169
109. Wang A., Loo R., Chen Z., and Dennis E.A. Regiospecificity and catalytic triad of lysophospholipase I. J Biol Chem 272 (1997) 22030-22036
110. Nakagawa Y., Sugai M., Karasawa K., et al. Possible influence of lysophospholipase on the production of 1-acyl-2-acetylglycerophosphocholine in macrophages. Biochim Biophys Acta 1126 (1992) 277-285
111. Xie Y., and Meier K.E. Lysophospholipase D and its role in LPA production. Cell Signal 16 (2004) 975-981
112. Jackson S.K., and Parton J. Lysophospholipid acyltransferases in monocyte inflammatory responses and sepsis. Immunobiology 209 (2004) 31-38
113. Zhao Y., Chen Y.Q., Bonacci T.M., et al. Identification and characterization of a major liver lysophosphatidylcholine acyltransferase. J Biol Chem 283 (2008) 8258-8265
114. Chen X., Hyatt B.A., Mucenski M.L., Mason R.J., and Shannon J.M. Identification and characterization of a lysophosphatidylcholine acyltransferase in alveolar type II cells. Proc Natl Acad Sci USA 103 (2006) 11724-11729
115. Soupene E., Fyrst H., and Kuypers F.A. Mammalian acyl-CoA: lysophosphatidylcholine acyltransferase enzymes. Proc Natl Acad Sci USA 105 (2008) 88-93
116. Kume N., Cybulsky M.I., and Gimbrone Jr. M.A. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90 (1992) 1138-1144
117. Rong J.X., Berman J.W., Taubman M.B., and Fisher E.A. Lysophosphatidylcholine stimulates monocyte chemoattractant protein-1 gene expression in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 22 (2002) 1617-1623
118. Takahara N., Kashiwagi A., Maegawa H., and Shigeta Y. Lysophosphatidylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 45 (1996) 559-564
119. Colles S.M., and Chisolm G.M. Lysophosphatidylcholine-induced cellular injury in cultured fibroblasts involves oxidative events. J Lipid Res 41 (2000) 1188-1198
120. Hsieh C.C., Yen M.H., Liu H.W., and Lau Y.T. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 151 (2000) 481-491
121. Matsubara M., Yao K., and Hasegawa K. Benidipine, a dihydropyridine-calcium channel blocker, inhibits lysophosphatidylcholine-induced endothelial injury via stimulation of nitric oxide release. Pharmacol Res 53 (2006) 35-43
122. Yan S., Chai H., Wang H., et al. Effects of lysophosphatidylcholine on monolayer cell permeability of human coronary artery endothelial cells. Surgery 138 (2005) 464-473
123. Wong J.T., Tran K., Pierce G.N., Chan A.C., and Choy P.C. Lysophosphatidylcholine stimulates the release of arachidonic acid in human endothelial cells. J Biol Chem 273 (1998) 6830-6836
124. Ceylan A., Karasu C., Aktan F., and Ozansoy G. Simvastatin treatment restores vasoconstriction and the inhibitory effect of LPC on endothelial relaxation via affecting oxidizing metabolism in diabetic rats. Diabetes Nutr Metab 17 (2004) 203-210
125. Chai Y.C., Howe P.H., DiCorleto P.E., and Chisolm G.M. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fibroblast growth factor-2. J Biol Chem 271 (1996) 17791-17797
126. Kohno M., Yokokawa K., Yasunari K., et al. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 98 (1998) 353-359
127. Liu-Wu Y., Hurt-Camejo E., and Wiklund O. Lysophosphatidylcholine induces the production of IL-1beta by human monocytes. Atherosclerosis 137 (1998) 351-357
128. Ousman S.S., and David S. Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 30 (2000) 92-104
129. Kita T., Kume N., Yokode M., et al. Oxidized-LDL and atherosclerosis. Role of LOX-1. Ann N Y Acad Sci 902 (2000) 95-100
130. Oka H., Kugiyama K., Doi H., et al. Lysophosphatidylcholine induces urokinase-type plasminogen activator and its receptor in human macrophages partly through redox-sensitive pathway. Arterioscler Thromb Vasc Biol 20 (2000) 244-250
131. Oestvang J., and Johansen B. PhospholipaseA2: a key regulator of inflammatory signalling and a connector to fibrosis development in atherosclerosis. Biochim Biophys Acta 1761 (2006) 1309-1316
132. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37 (2004) 1304-1316
133. Yamamoto M., Hara H., and Adachi T. The expression of extracellular-superoxide dismutase is increased by lysophosphatidylcholine in human monocytic U937 cells. Atherosclerosis 163 (2002) 223-228
134. Rosenblat M., Vaya J., Shih D., and Aviram M. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Atherosclerosis 179 (2005) 69-77
135. Rosenblat M., Gaidukov L., Khersonsky O., et al. The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281 (2006) 7657-7665
136. Ryborg A.K., Deleuran B., Thestrup-Pedersen K., and Kragballe K. Lysophosphatidylcholine: a chemoattractant to human T lymphocytes. Arch Dermatol Res 286 (1994) 462-465
137. Weber C., Erl W., and Weber P.C. Enhancement of monocyte adhesion to endothelial cells by oxidatively modified low-density lipoprotein is mediated by activation of CD11b. Biochem Biophys Res Commun 206 (1995) 621-628
138. Nakano T., Raines E.W., Abraham J.A., Klagsbrun M., and Ross R. Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci USA 91 (1994) 1069-1073
139. Nishi E., Kume N., Ochi H., et al. Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes. Circ Res 80 (1997) 638-644
140. Hoffman R.D., Kligerman M., Sundt T.M., Anderson N.D., and Shin H.S. Stereospecific chemoattraction of lymphoblastic cells by gradients of lysophosphatidylcholine. Proc Natl Acad Sci USA 79 (1982) 3285-3289
141. Kume N., and Gimbrone Jr. M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 93 (1994) 907-911
142. Mueller R.B., Sheriff A., Gaipl U.S., Wesselborg S., and Lauber K. Attraction of phagocytes by apoptotic cells is mediated by lysophosphatidylcholine. Autoimmunity 40 (2007) 342-344
143. Lauber K., Bohn E., Krober S.M., et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113 (2003) 717-730
144. Fujimoto W.Y., and Teague J. Phasic effects of glucose, p-hydroxymercuribenzoate, and lysophosphatidylcholine on insulin secretion from HIT cells. Diabetes 38 (1989) 625-628